Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;58(3):429-39.
doi: 10.1007/s00262-008-0569-3. Epub 2008 Aug 22.

Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis

Affiliations

Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis

Ingrid M Overes et al. Cancer Immunol Immunother. 2009 Mar.

Abstract

CD8(+) T cells recognizing minor histocompatibility antigens (MiHA) on solid tumor cells may mediate effective graft-versus-tumor (GVT) reactivity after allogeneic stem cell transplantation (SCT). Previously, we identified LRH-1 as a hematopoietic-restricted MiHA encoded by the P2X5 gene. Here, we report that LRH-1 is aberrantly expressed on solid tumor cells. P2X5 mRNA expression is demonstrated in a significant portion of solid tumor cell lines, including renal cell carcinoma (RCC), melanoma, colorectal carcinoma, brain cancer and breast cancer. Importantly, P2X5 gene expression was also detected in a subset of primary solid tumor specimens derived from RCC, brain cancer and breast cancer patients. Furthermore, P2X5 expressing solid tumor cells can be effectively targeted by LRH-1-specific cytotoxic T lymphocytes under inflammatory conditions. The expression of HLA-B7 and CD54 on tumor cells increases upon cytokine stimulation resulting in improved T cell activation as observed by higher levels of degranulation and enhanced tumor cell lysis. Overall, hematopoietic-restricted MiHA LRH-1 is aberrantly expressed on solid tumor cells and may be used as target in GVT-specific immunotherapy after SCT.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
P2X5 gene expression in solid tumor cells. P2X5 mRNA expression was determined by real-time quantitative RT-PCR in 42 solid tumor cell lines. Cell lines from the following tumor types were analyzed: renal cell carcinoma (RCC; n = 11), melanoma (n = 4), colorectal carcinoma (n = 7), brain cancer (n = 10), and breast cancer (n = 10). Expression is shown relative to the P2X5 expression measured in reference B-cell line JVM-2, which is susceptible to lysis by LRH-1-specific CTL. The housekeeping gene HMBS was used for normalization. Solid tumor cell lines with P2X5 expression higher than 0.4 were considered positive and potential targets for LRH-1-specific CTL, based on previous expression and recognition studies. This arbitrary threshold is indicated with a dashed line
Fig. 2
Fig. 2
Cytotoxicity against solid tumor cell lines was determined after incubation with LRH-1-specific CTL (filled up triangle), HLA-B7-specific CTL (filled inverted triangle; positive control) or medium only (filled diamond). Survival of unstimulated and cytokine-stimulated target cells in the absence or presence of CTL at an E:T ratio of 3:1 is shown of an LRH-1 + and LRH-1 EBV-LCL (a) and of LRH-1+ brain tumor cell line DAOY (b). P2X5 mRNA expression is shown between parentheses. Data are depicted as mean ± SD of triplicate wells. c Microscopic analysis of cytokine-stimulated DAOY cells at 40 h of co-culture with CTL or medium
Fig. 3
Fig. 3
Cytotoxicity against LRH-1 + melanoma cell line BLM (a) and LRH-1 melanoma cell line FM3 (b) was determined after incubation with LRH-1-specific CTL (filled up triangle), HLA-B7-specific CTL (filled inverted triangle; positive control) or medium only (filled diamond). Survival of unstimulated and cytokine-stimulated target cells in the absence or presence of CTL at an E:T ratio of 3:1 is shown. P2X5 mRNA expression is shown between parentheses. Data are depicted as mean ± SD of triplicate wells
Fig. 4
Fig. 4
Cytotoxicity against LRH-1 + RCC cell lines SKRC33 (a) and SKRC18 (b) was determined after incubation with LRH-1-specific CTL (filled up triangle), HLA-B7-specific CTL (filled inverted triangle; positive control) or medium only (filled diamond). Survival of unstimulated and cytokine-stimulated target cells in the absence or presence of CTL at an E:T ratio of 3:1 is shown. P2X5 mRNA expression is shown between parentheses. Data are depicted as mean ± SD of triplicate wells. c LRH-1-peptide loading resulted in improved lysis of SKRC18
Fig. 5
Fig. 5
a The expression of adhesion and MHC molecules in epithelial cancer cell lines. Surface expression of HLA-B7, CD54 (ICAM-1) and CD58 (LFA-3) was determined by flow cytometry. Prior to analysis cells were cultured for 4 days in the absence or presence of inflammatory cytokines IFNγ and TNFα. Data are depicted as fold induction of the mean fluorescence intensity (MFI) upon cytokine stimulation. b Cytokine stimulation of cancer cells results in improved degranulation of CTL. Anti-CD107-antibody was added to the co-cultures of flow cytometry-based cytotoxicity assays. Degranulation of LRH-1-specific CTL was measured after 1 day of co-culture with solid tumor cell lines and control EBV-LCL. Data are depicted as mean ± SD of triplicate measurements

Similar articles

Cited by

References

    1. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology. 2004;19(4):216–224. doi: 10.1152/physiol.00002.2004. - DOI - PubMed
    1. Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. Cancer Sci. 2007;98(8):1139–1146. doi: 10.1111/j.1349-7006.2007.00521.x. - DOI - PMC - PubMed
    1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411(6835):385–389. doi: 10.1038/35077251. - DOI - PubMed
    1. Arya M, Chao D, Patel HR. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Nat Clin Pract Oncol. 2004;1(1):32–38. doi: 10.1038/ncponc0019. - DOI - PubMed
    1. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99(11):4234–4236. doi: 10.1182/blood.V99.11.4234. - DOI - PubMed

Publication types

MeSH terms